A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1417-1424

  Bhat, V K ^a   Kerr, B D ^a   Vasu, S ^a   Flatt, P R ^a   Gault, V A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Glucagon; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Glucose lowering; Insulin secretion; Type 2 diabetes

Indexed keywords

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON[1 TYROSINE 2 DEXTRO ALANINE 12 ISOLEUCINE 17 ASPARAGINE 18 VALINE 27 ISOLEUCINE 28,29 GLYCINE]; GLUCOSE; HORMONE RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PURIFICATION; DRUG SYNTHESIS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CRICETINAE; CRICETULUS; DIET, HIGH-FAT; DIPEPTIDYL PEPTIDASE 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEK293 CELLS; HOMEOSTASIS; HUMANS; INSULIN; MALE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON;

EID: 84877763087     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2892-2     Document Type: Article

References (29)

1. Cryer PE (2012) Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039-1048
2. Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metabol 1:22-31
3. Del Prato S, Marchetti P (2004) Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 36:775-781
4. Christensen M, Bagger JI, Vilsbøll T, Knop FK (2011) The alpha-cell as target for type 2 diabetes. Rev Diabet Stud 8:369-381
5. Bagger JI, Knop FK, Holst JJ, Vilsbøll T (2011) Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metabol 13:965-971
6. Agius L (2007) New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metabol 21:587-605
7. Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100:1438-1443
8. Gelling RE, Vuguin PM, Du XQ et al (2009) Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab 297:E695-E707
9. Vuguin PM, Charron MJ (2011) Novel insights into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes Metabol 13:144-150
10. Pocai A, Carrington PE, Adams JR et al (2009) Glucagon-like peptide-1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258-2266
11. Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749-757
12. Maida A, Lovshin JA, Baggio LL, Drucker DJ (2008) The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 149:5670-5678
13. 2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemia, insulinotropic and anorexigenic actions. Biochem Pharmacol 80:1727-1735
14. Druce MR, Minnion JS, Field BC et al (2008) Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150:1712-1722
15. Du X, Kosinski JR, Lao J et al (2012) Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. Am J Physiol Endocrinol Metab 303:E265-E271
16. Santoprete A, Capito E, Carrington PE et al (2011) DPP-IV-resistant, long-acting oxyntomodulin derivatives. J Pept Sci 17:270-280
17. Liu YL, Ford HE, Druce MR et al (2010) Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes (Lond) 34:1715-1725
18. Gault VA, Flatt PR, O'Harte FP Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 308:207-213
19. Irwin N, Green BD, Gault VA et al (2005) Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivatized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J Med Chem 48:1244-1250
20. McClenaghan NH, Barnett CR, Ah-Sing E et al (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electro-fusion. Diabetes 45:1132-1140
21. Gremlich S, Porret A, Hani EH et al (1995) Cloning, functional expression and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208
22. Thorens B, Porret A, Buhler L et al (1993) Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682
23. Ikegami T, Cypess AM, Bouscarel B (2001) Modulation of glucagon receptor expression and response in transfected human embryonic kidney cells. Am J Physiol Cell Physiol 281:1396-1402
24. Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573-577
25. Fields GB, Noble RL (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214
26. Hinke SA, Gelling RW, Pederson RA et al (2002) Dipeptidyl peptidase IV-resistant [d-Ala2]glucose-dependent insulinotropic polypeptide polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51:652-661
27. Gallwitz B (2011) Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 71:1675-1688
28. Aaboe K, Knop FK, Vilsboll T et al (2009) KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 4:603-608
29. Hojberg PV, Vilsboll T, Rabol R et al (2009) Four weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207